On January 5, 2026, Andrew Callos, Executive Vice President of Cytokinetics, executed a sale of 15,000 CYTK shares, reducing his total holdings to 50,440 shares, according to SEC filings. This follows two December transactions in which Callos sold 1,042 shares on December 8 and 52,486 shares on December 5, with the combined proceeds reported as approximately $3.46 million. These disclosures provide investors with transparent insights into senior management’s trading activity and raise questions about insider sentiment as the company advances its clinical and commercial programs.

Cytokinetics CEO Robert I. Blum is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 9:45 AM Pacific Time. The presentation will review the company’s commercial launch of MYQORZO™ (aficamten) for obstructive hypertrophic cardiomyopathy in the U.S. and China, the positive CHMP opinion for European approval expected in Q1 2026, and progress on pipeline candidates including omecamtiv mecarbil for heart failure with reduced ejection fraction, ulacamten for preserved ejection fraction, and early-stage muscle biology programs. Investors can access the live webcast via the Cytokinetics website, with the replay archived for 90 days.